Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $36.0 million.

  • Maravai Lifesciences Holdings' Cost of Revenue fell 221.79% to $36.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $151.9 million, marking a year-over-year increase of 207.03%. This contributed to the annual value of $150.9 million for FY2024, which is 143.4% up from last year.
  • As of Q3 2025, Maravai Lifesciences Holdings' Cost of Revenue stood at $36.0 million, which was down 221.79% from $39.6 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' 5-year Cost of Revenue high stood at $53.3 million for Q4 2022, and its period low was $31.4 million during Q1 2021.
  • For the 5-year period, Maravai Lifesciences Holdings' Cost of Revenue averaged around $38.1 million, with its median value being $37.8 million (2021).
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Cost of Revenue soared by 10521.02% in 2021 and then tumbled by 3407.32% in 2023.
  • Quarter analysis of 5 years shows Maravai Lifesciences Holdings' Cost of Revenue stood at $39.1 million in 2021, then surged by 36.06% to $53.3 million in 2022, then plummeted by 34.07% to $35.1 million in 2023, then grew by 5.87% to $37.2 million in 2024, then fell by 3.21% to $36.0 million in 2025.
  • Its Cost of Revenue stands at $36.0 million for Q3 2025, versus $39.6 million for Q2 2025 and $39.1 million for Q1 2025.